Suppliers / 3D Imaging Drug Design and Development

3D Imaging Drug Design and Development

United States Updated 9 July 2026

3D Imaging Drug Design and Development is an API manufacturer based in United States. It holds one active US drug master file. Its most recent recorded inspection, by US FDA, closed on 13 June 2025 as OAI.

1
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
3
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 13 June 2025 OAI US FDA
  • 31 January 2024 VAI US FDA
  • 20 April 2017 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Little Rock, United States 3009143510

What they file, and where

Molecule Regulators Docs
Clofarabine US FDA 1

Also appears on these molecule pages

Clofarabine API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 3 None

Comparing suppliers?

Choose your molecules and target markets. 3D Imaging Drug Design and Development comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was OAI, on 13 June 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability